Poster
Molecular Analysis of Circulating Tumor DNA in Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC Treated With Mobocertinib
Author
Sylvie Vincent
Condition
non–small cell lung cancer (NSCLC)
Drug target
EGFR exon 20 insertion (ex20ins)
Drug moa
irreversible covalent bond with Cys797 in EGFR and increased affinity for the EGFR ex20ins mutant
Date
2022
Source url
s3://convoke-optic-posters/8b83745f-205a-4203-b81e-7dfa60f4b940.pdf
1 organization
1 product
Product
Mobocertinib